Hologic Inc Stock Price, News & Analysis

Hologic, Inc. (NASDAQ: HOLX) announced data showcasing the Breast Cancer Index™ (BCI) as a key tool predicting treatment benefits in hormone receptor-positive (HR+) breast cancer patients. Presented at the 2021 San Antonio Breast Cancer Symposium, findings reveal that BCI predicts recurrence-prevention advantages from extended endocrine therapy (EET) and highlights biomarkers critical for assessing treatment effectiveness. The research emphasizes patient compliance and informed decisions, confirming significant net treatment benefits while considering adverse effects. BCI is unique in guiding individualized treatment decisions.

Hologic, Inc. (NASDAQ: HOLX) has finalized its acquisition of Bolder Surgical, enhancing its laparoscopic device portfolio aimed at women's health. This strategic move integrates Bolder's advanced energy vessel sealing technologies, including the CoolSeal^® Vessel Sealing Suite, into Hologic's offerings. The acquisition is expected to provide better surgical options for OB/GYN specialists and broaden Hologic's market presence in minimally invasive treatments.

Hologic, Inc. (Nasdaq: HOLX) announced that its SARS-CoV-2 tests successfully detect the new Omicron variant. The tests, including the Aptima SARS-CoV-2 Assay, were verified through genetic sequencing of over 175 samples. Hologic's assays are stated to be unaffected by the variant's mutations. With over 130 million SARS-CoV-2 tests distributed, the company has significantly impacted global testing. The automated Panther systems can process over 1,000 tests daily.

Hologic, Inc. (NASDAQ: HOLX) will showcase its breast and skeletal health innovations at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 28 to Dec. 2 at McCormick Place, booth #2511. The event features hands-on experiences with various products, including the Dimensions® mammography portfolio and Mach™ ultrasound systems.

Attendees can participate in CME and non-CME medical education sessions, discussing advanced topics like 3D-guided biopsies and AI in breast imaging.

Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 4th Annual Evercore ISI HealthCONx Conference on November 30 at 9:40 a.m. Eastern Time. The presentation will be accessible via a link on Hologic’s investors page, and the webcast will be available for 30 days post-event. Hologic is dedicated to enhancing women’s health and well-being through innovative medical technologies for early detection and treatment.

Hologic, Inc. (Nasdaq: HOLX) has launched its innovative Genius™ Digital Diagnostics System in Europe, enhancing cervical cancer screening with artificial intelligence and advanced imaging. This system aims to identify pre-cancerous lesions and cervical cancer cells more effectively. The Genius system is designed to improve lab efficiency and workflow while promoting collaboration among laboratories. Customer feedback has been overwhelmingly positive, highlighting its potential to transform screening processes and enhance patient outcomes.

Hologic, Inc. (NASDAQ: HOLX) is set to launch the NovaSure® V5 global endometrial ablation device at the AAGL 50th Global Congress (November 14-17). This innovative device, building on a 20-year legacy of the NovaSure system, aims to enhance the physician experience. With over 3 million treatments performed since its FDA approval in 2001, the device incorporates advanced features like the EndoForm™ cervical seal technology and SureClear™ fluid removal system. The launch reflects Hologic's commitment to improving outcomes for women and providing physicians with reliable tools.

Hologic, Inc. (HOLX) reported a fiscal Q4 2021 revenue of $1.317 billion, slightly below last year but exceeding expectations. GAAP diluted EPS was $1.28, down 31.9% year-over-year, while non-GAAP diluted EPS was $1.61, down 22.2%. The company anticipates solid growth in core women's health businesses for fiscal 2022, projecting revenues of $3.750B to $4.000B. Key highlights include a 47% annual revenue growth driven by women's health and COVID-19 testing, although COVID-19 assay sales decreased substantially. Strong operational cash flow of $465.4 million was reported for Q4.

Hologic, Inc. has launched the Aptima® SARS-CoV-2/Flu Assay for simultaneous detection of SARS-CoV-2, influenza A, and influenza B. The assay, CE-Marked for Europe and FDA authorized, provides results in approximately three hours and can process over 1,000 tests daily. This multiplex test addresses the overlap of symptoms between these viruses, enhancing testing options as the flu season approaches. Hologic has distributed over 100 million SARS-CoV-2 assays globally.